These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10449120)

  • 21. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.
    Nutt JG; Woodward WR; Carter JH; Gancher ST
    Arch Neurol; 1992 Nov; 49(11):1123-30. PubMed ID: 1444877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
    Nutt JG; Chung KA; Holford NH
    Neurology; 2010 Apr; 74(15):1191-7. PubMed ID: 20220120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
    Metman LV; van den Munckhof P; Klaassen AA; Blanchet P; Mouradian MM; Chase TN
    Neurology; 1997 Sep; 49(3):711-3. PubMed ID: 9305328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of the response to levodopa during the first 4 years of therapy.
    Nutt JG; Carter JH; Lea ES; Sexton GJ
    Ann Neurol; 2002 Jun; 51(6):686-93. PubMed ID: 12112073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.
    Doi H; Sakakibara R; Sato M; Masaka T; Kishi M; Tateno A; Tateno F; Tsuyusaki Y; Takahashi O
    J Neurol Sci; 2012 Aug; 319(1-2):86-8. PubMed ID: 22632782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
    Blindauer K; Shoulson I; Oakes D; Kieburtz K; Schwid S; Fahn S; Stern M; Goetz C; Nutt J; Goren S; Sayag N; Scolnik M; Levy R; Eyal E; Salzman P; Pagano M;
    Arch Neurol; 2006 Feb; 63(2):210-6. PubMed ID: 16476809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-duration response to levodopa.
    Nutt JG; Carter JH; Woodward WR
    Neurology; 1995 Aug; 45(8):1613-6. PubMed ID: 7644063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients.
    Nutt JG; Woodward WR
    Neurology; 1986 Jun; 36(6):739-44. PubMed ID: 3703280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
    Nutt JG; Woodward WR; Beckner RM; Stone CK; Berggren K; Carter JH; Gancher ST; Hammerstad JP; Gordin A
    Neurology; 1994 May; 44(5):913-9. PubMed ID: 8190296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.
    Hardie RJ; Lees AJ; Stern GM
    Brain; 1984 Jun; 107 ( Pt 2)():487-506. PubMed ID: 6722513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
    López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
    Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
    Nutt JG; Carter JH; Woodward W; Hammerstad JP; Gancher ST
    Mov Disord; 1993 Apr; 8(2):139-43. PubMed ID: 8474479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.